Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke

JAMA Neurology

Volumn 71, Issue 5, 2014, Pages 634-639

  Neuhaus, Ain A ^a   Rabie, Tamer ^a   Sutherland, Brad A ^a   Papadakis, Michalis ^a   Hadley, Gina ^a   Cai, Ruiyao ^b   Buchan, Alastair M ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; INTERLEUKIN 1; NA 1 PEPTIDE; NEUROPROTECTIVE AGENT; POSTSYNAPTIC DENSITY PROTEIN 95; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; DRUG EFFICACY; HUMAN; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84900478304     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.6299     Document Type: Review

References (45)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
2. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemiathe ischemic penumbra. Stroke. 1981;12(6):723-725.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
4. Balami JS, Hadley G, Sutherland BA, Karbalai H, Buchan AM. The exact science of stroke thrombolysis and the quiet art of patient selection. Brain. 2013;136(pt 12):3528-3553.
5. OCollins VE, Macleod MR, Donnan GA, Horky LL, van derWorp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467-477.
6. Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J AmMed Assoc. 1958;167(14):1705-1709.
7. Ames A III,Wright RL, Kowada M, Thurston JM, Majno G. Cerebral ischemia: II, the no-reflow phenomenon. Am J Pathol. 1968;52(2):437-453.
8. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff J. Free radicals in cerebral ischemia. Stroke. 1978;9(5):445-447.
9. PulsinelliWA, Brierley JB. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke. 1979;10(3):267-272.
10. Tamura A, Graham DI,McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat: 1, description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1(1):53-60.
11. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 1982;239(1):57-69.
12. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci. 1984;4(7):1884-1891.
13. Longa EZ,Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84-91.
14. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 1994;36(4):557-565.
15. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391-397.
16. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752-2758.
17. Lees KR, Asplund K, Carolei A, et al; GAIN International Investigators. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet. 2000;355(9219):1949-1954.
18. Shuaib A, Lees KR, Lyden P, et al; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6): 562-571.
19. Guo S, Lo EH. Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke. 2009;40(3 suppl):S4-S7.
20. Sutherland BA,Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke. 2012;7(5):407-418.
21. Gladstone DJ, Black SE, Hakim AM; Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123- 2136.
22. Traystman RJ. Animal models of focal and global cerebral ischemia. ILAR J. 2003;44(2):85-95.
23. Macrae IM. Preclinical stroke researchadvantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol. 2011;164(4):1062-1078.
24. PapadakisM, Hadley G, XilouriM, et al. Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nat Med. 2013;19(3):351-357.
25. Howells DW, Macleod MR. Evidence-based translational medicine. Stroke. 2013;44(5):1466- 1471.
26. Buchan A, PulsinelliWA. Hypothermia but not the N-methyl-D-aspartate antagonist,MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J Neurosci. 1990;10(1):311-316.
27. Buchan AM, Slivka A, Xue D. The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res. 1992;574(1-2):171-177.
28. Sutherland BA, PapadakisM, Chen RL, Buchan AM. Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol. 2011;589(pt 17):4105-4114.
29. PapadakisM, Nagel S, Buchan AM. Development and efficacy of NXY-059 for the treatment of acute ischemic stroke. Future Neurol. 2008;3(3):229-240. doi:10.2217 /14796708.3.3.229.
30. Fisher M, Feuerstein G, Howells DW, et al; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244- 2250.
31. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40(2):577-581.
32. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 2002;298(5594):846-850.
33. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483(7388):213-217.
34. Hill MD, Martin RH, Mikulis D, et al; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11(11):942-950.
35. Denes A, Pinteaux E, Rothwell NJ, Allan SM. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis. 2011;32(6):517-527.
36. Emsley HC, Smith CJ, Georgiou RF, et al; Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76(10):1366-1372.
37. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356.
38. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
39. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol. 2011;37(1):3-23.
40. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009;8(5):491-500.
41. Obenaus A, Ashwal S. Neuroimaging of stroke and ischemia in animal models. Transl Stroke Res. 2012;3(1):4-7.
42. Shih AY, Driscoll JD, Drew PJ, Nishimura N, Schaffer CB, Kleinfeld D. Two-photon microscopy as a tool to study blood flow and neurovascular coupling in the rodent brain [published correction appears in J Cereb Blood Flow Metab. 2013;33(2):319]. J Cereb Blood Flow Metab. 2012;32(7):1277-1309.
43. VanGilder RL, Huber JD, Rosen CL, Barr TL. The transcriptome of cerebral ischemia. Brain Res Bull. 2012;88(4):313-319.
44. Dirnagl U, Hakim A, Macleod M, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke. 2013;44(6):1754-1760.
45. Donnan GA. The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke. 2008;39(1):242.